BRAF and melanoma: Recently, two important compounds changed the history of treatment for advanced melanoma: the anti- cytotoxic T-lymphocyte antigen 4 (CTLA4) monoclonal antibody [4,5] among unselected patients and the BRAF inhibitors (BRAFi) [6] among patients carrying a mutation at the valine 600 codon in the BRAF gene (V600EBRAF mutation).